Dr. Sashi Naidu, MD

Dr. Naidu practices at Carolina Blood and Cancer Care Associates, P.A. in Rock Hill, South Carolina.

Dr. Naidu's NPI, 1245327279, was assigned on October 10, 2006. Dr. Naidu holds South Carolina license 28287.

Dr. Naidu's primary practice is Carolina Blood and Cancer Care Associates, P.A., at 1583 Health Care Dr, Rock Hill, SC 29732 in York County. The practice phone is (803) 329-7772.

Dr. Naidu's primary practice is Carolina Blood and Cancer Care Associates, P.A. in Rock Hill, South Carolina. Dr. Naidu is also affiliated with Rock Hill Hospital - Piedmont Medical Network. The medical group on file is Carolina Blood and Cancer Care. Dmand AI also links Dr. Naidu to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Naidu practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Naidu's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Naidu's licenses on file in 2 states: South Carolina and North Carolina.

CMS data shows 12,094 Medicare services from Dr. Naidu across 32 procedure codes in 2024, for 443 Medicare patients. Medicare paid $198,243 for them. Every service was in an office.

CMS counts 443 Medicare patients who saw Dr. Naidu in 2024. The largest group is 65 to 74, with 182 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Naidu's median patient age at 70, with 64% women.

In 2024, Dr. Naidu wrote 867 Medicare Part D claims for 142 patients. 50% of them were for generic drugs. CMS names the drug for 684 of them, across 23 drugs with 11 or more claims each, at $1,991,805 in total drug cost. In 2023, CMS named 604 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Naidu for performance year 2024, reported individually. Dr. Naidu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Naidu as offering telehealth.

Dmand AI links Dr. Naidu to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell and Leukemia, B-Cell. Open Payments lists research payments to Dr. Naidu that name 2 trials.

CMS Open Payments shows 1,458 general payments to Dr. Naidu from 94 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 45% of the total. Genentech, Inc. paid the most, $6,799. It also lists 4 research payments totaling $24,136 from 2017 to 2023, naming 2 clinical trials.